youarewithinthenorms.com
NORMAN J CLEMENT RPH., DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC., SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS, MD, PH.D., IN THE SPIRIT OF C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., M.B.A., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., EVELYN J. CLEMENT, WALTER F. WRENN III., MD., JULIE KILLINGSWORTH, RENEE BLARE, RPH, DR. TERENCE SASAKI, MD LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, IN THE SPIRIT OF WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., IN THE SPIRIT OF RICHARD KAUL, MD., IN THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., MBA, AISHA GARDNER, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS
Dear Dr. Pantazis,
I hope you are doing well.
I am writing to you as a chronic pain patient who is currently preparing an opposition to a motion to dismiss in a federal case concerning access to medical care under the Americans with Disabilities Act and Section 504 of the Rehabilitation Act. The case involves questions of whether systemic constraints on individualized treatment can result in meaningful functional impairment for patients with severe chronic pain.
While researching the biological foundations of pain, I came across your work at Linköping University examining the role of CaV2.2 calcium channels in modulating and amplifying pain signaling.
Your findings describing pain as a dynamic and regulated process, rather than a static symptom, provide an important scientific framework for understanding how insufficiently controlled pain may contribute to ongoing physiological dysfunction.
I would be grateful for your permission to cite your research in my legal briefing for the limited and accurate purpose of explaining these biological mechanisms to the court. I will ensure that your work is represented faithfully and in proper context.
Thank you for your contributions to advancing the scientific understanding of pain. Your research has provided clarity that is both scientifically and personally meaningful.
low-dose naltrexone (LDN)
At this stage, I do not consider low-dose naltrexone (LDN) to be an appropriate intervention. Emerging evidence and clinical observation suggest that persistent, inadequately controlled pain is not physiologically neutral, but rather represents an active and destabilizing process that may contribute to both the onset and progression of autonomic dysfunction. In this context, introducing LDN without first stabilizing the underlying drivers of pain may be premature.
There is also a strong indication that latent viral activity, particularly from Epstein-Barr virus, is contributing to both immune dysregulation and pain amplification. Accordingly, priority should be given to addressing underlying infectious or inflammatory processes where clinically appropriate, while simultaneously improving pain control to reduce ongoing physiological stress and potential autonomic burden.
A more coherent treatment sequence would involve stabilizing pain through appropriate analgesic strategies, followed by a gradual and carefully monitored reduction of Pregabalin as tolerated. In parallel, structured physical rehabilitation, including graded movement and supportive physical therapies, should be incrementally introduced to restore function without exacerbating symptoms.
The predominant therapeutic objective at this stage is stabilization of the neuroimmune and autonomic environment, rather than premature modulation of immune pathways through agents such as LDN.
The researcher shows that the current Federal program for pain management is already proven inadequate
With respect,
Kenneth Pettingill
Scientifically
TO CASH APP:$docnorm
ZELLE 3135103378
ALL WATCHED OVER BY MACHINES OF LOVING GRACE
BE SURE TO DONATE TO THE MARK IBSEN GOFUNDME DEFENSE FUND, WHERE THE SON ALWAYS RISES!!!
FOR NOW, YOU ARE WITHIN
THE NORMS
REFERENCES:
B. The Pharmacological Trinity-1 While opioids target G-protein-coupled receptors to block pain signals, benzodiazepines enhance GABAergic inhibition to provide necessary sedation and muscle relaxation. This synergistic approach allows for lower medication doses, which effectively reduces adverse side effects while extending the duration of relief. Beyond clinical mechanics, the text uses a theological metaphor of the Holy Trinity to illustrate how these distinct agents work in dynamic communion to heal the patient. Ultimately, the goal of this integrated therapy is to restore the individual’s quality of life, enabling them to return to employment, mobility, and social connection.
